EUVIMEDEUVIMED entdecken
CrossrefInfokarte

A Review of Prescription Drug Affordability Boards

Kwame Kissi-Twum, T. Joseph Mattingly II

Journal of Healthcare Finance · 2026-09-15 · 16

DOI: 10.68415/x1n3ts77 ↗
AbstractBibliografische Angaben

Abstract

Background: In the United States, rising prescription drug costs are a growing concern for policymakers. In response, several states have established Prescription Drug Affordability Boards (PDABs) to evaluate high-cost drugs, assess their affordability for patients and payers, and, where authorized, establish upper payment limits (UPLs). Objectives: To characterize statutory and governance differences across PDABs, examine how each state defines and operationalizes “affordability” in policy and law, and synthesize quantitative data on drugs selected for affordability review or UPL consideration. Methods: We identified PBABs that were active as of October 24, 2025. We included state entities that had the authority to conduct drug affordability reviews or use strategies such as UPLs. We excluded entities that functioned exclusively as price transparency or data-reporting commissions. For each state, we reviewed enabling statutes and publicly released data files. We extracted data on statutory design, governance structure, affordability definitions, and drugs identified for affordability review, and summarized cross-state similarities and differences. Results: We identified 5 PDABs in Maryland, Colorado, Oregon, Washington, and Minnesota. Across states, boards required expertise in clinical medicine or healthcare economics. Drugs were identified for affordability reviews based on wholesale acquisition costs (WAC) thresholds, such as WAC increases of $300 or more or 200% or more in the prior 12 months, or an annual WAC of $30,000 or more. For biosimilars, 4 PDABs considered whether they were launched at a 15% or 20% discount relative to the reference biologic. Drugs that progressed to full review were high-cost specialty therapies with high per-patient spending or rapid price growth, such as Enbrel. Conclusion: PDABs share common structural features across states, but the extent of implementation differs. Although the long-term impact of PDABs on payer spending is uncertain, variation in transparency and prioritization across boards may influence how these policies evolve over time.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →